.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Boston Scientific recently announced a significant TAVR system investment in MiRus LLC, a move that signals their aggressive return to the heart valve market. This $1.5 billion deal secures a 34% equity stake in the privately held startup. Furthermore, the agreement provides a clear path for a potential full acquisition of the heart-valve business. Consequently, this partnership highlights the growing importance of advanced transcatheter technologies in modern cardiology.
The primary driver behind this TAVR system investment is the development of the SIEGEL valve. Currently, the creators of this experimental device intend it for patients suffering from severe aortic stenosis. Notably, the SIEGEL valve aims to offer a balloon-expandable solution, a sector Boston Scientific exited previously. However, rising demand for minimally invasive cardiac procedures prompted this strategic pivot. In addition, the deal includes potential acquisition rights for mitral and tricuspid valve assets.
Boston Scientific previously exited the balloon-expandable market due to complex regulatory hurdles. Now, the company aims to meet those challenges through the innovative technology developed by MiRus. Specifically, the SIEGEL valve represents a next-generation approach to treating valvular narrowing. If MiRus achieves specific clinical milestones, Boston Scientific may pay an additional $3 billion for full ownership. This underscores their commitment to leading the cardiovascular device space globally. Moreover, the investment will likely influence the competitive landscape for TAVR systems in the coming years.
Q1: What is the purpose of the SIEGEL valve mentioned in the deal?
The SIEGEL valve is an experimental balloon-expandable device designed to treat patients with severe aortic stenosis. It is not currently approved for commercial sale in any country.
Q2: Why did Boston Scientific decide to re-enter the TAVR market?
Boston Scientific is re-entering this market to capture growth in the balloon-expandable segment, despite their previous exit due to high clinical and regulatory requirements.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Boston Scientific invests $1.5 billion in MiRus LLC to re-enter the TAVR market, focusing on the experimental SIEGEL valve for treating aortic stenosis....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
